All seven independent members of US biotechnology firm 23andMe's board have resigned following a months-long battle over CEO and Co-founder Anne Wojcicki's plan to take the firm private. 23andMe has never turned a profit since it went public after a merger in 2021. Differences over the firm's "strategic direction" and Wojcicki's control of 49% votes led to the board's resignation.